The settlement resolves allegations against pharmaceutical heavyweights Shire PLC, Baxter International Inc., Baxalta Inc., Viropharma Inc., Takeda Pharmaceuticals U.S.A., Inc., and Takeda Pharmaceuticals America for violations of the Texas Medicaid Fraud Prevention Act. The companies allegedly engaged in practices that resulted in fraudulent billing to the state's Medicaid program, costing Texas taxpayers millions in improper payments.
While the Attorney General's office did not detail the specific allegations in the August 8, 2023 announcement, the settlement represents the culmination of a civil enforcement action that targeted the companies' Medicaid billing practices. The recovery will return funds to the state treasury that were improperly paid out through the Medicaid program.
The pharmaceutical settlement is part of a broader crackdown by Paxton's office on healthcare fraud schemes across Texas. Since July 2023, the Attorney General's Medicaid Fraud Control Unit has secured convictions and settlements totaling over $200 million, targeting everything from genetic testing scams to ambulance company fraud.
The enforcement action follows a pattern of aggressive prosecution by Texas authorities. In recent months, the state has dismantled a $142 million genetic testing fraud scheme, secured prison sentences for ambulance company owners, and prosecuted home health care providers for kickback schemes ranging from $1.4 million to $6.9 million.
The pharmaceutical companies' alleged violations centered on their participation in practices that led to fraudulent Medicaid claims, though the specific nature of the misconduct was not disclosed in the settlement announcement. The Texas Medicaid Fraud Prevention Act allows the state to recover damages and penalties from entities that submit false claims or engage in fraudulent billing practices.
The $42.7 million recovery stands as one of the largest individual settlements in Texas Attorney General Paxton's healthcare fraud enforcement efforts. The Medicaid Fraud Control Unit has been particularly active in 2023, with multiple high-profile prosecutions resulting in significant prison sentences and restitution orders for defendants across the healthcare spectrum.
The settlement marks a significant victory for Texas taxpayers, who fund the state's Medicaid program. The recovered funds will be returned to the state treasury, helping to offset the costs of fraudulent payments made through the program.